European Court of Appeal Rejects Varian's Attempt to Reverse Customer Purchase of Accuray TomoTherapy(R) System
SUNNYVALE, Calif., Oct. 19, 2017 -- (Healthcare Sales &Marketing Network) -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Court of Appeal of Nantes has rejected the appeal filed by Varian Medical Systems opposing the purchase of the Accur... Devices, Oncology, Litigation Accuray, Varian Medical Systems, TomoTherapy, radiotherapy, IMRT
Conditions: Oropharynx Cancer; Oropharynx Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Carcinoma; Oropharyngeal Neoplasms; Neoplasms, Squamous Cell; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Pharyngeal Neoplasms Malignant and Unspecif ied; Otorhinolaryngologic Neoplasms; Head and Neck Neoplasms; Neoplasms by Site; Otorhinolaryngologic Diseases; Pharyngeal Diseases...
CONCLUSION: The overexpression of p53 and eIF4E in pathologically negative margins may represent a subset of patients who would benefit from early initiation of adjuvant radiation and tailored intensity-modulated radiotherapy (IMRT).
Older patients undergoing radiation therapy (RT) for pelvic malignancies are at increased risk for pelvic fracture, which is associated with significant morbidity and mortality. RT techniques such as brachytherapy or intensity modulated RT (IMRT) allow for more conformal dose distributions, but it is not known whether the risk for pelvic fracture varies by RT modality.
UK neuro-oncologists and multidisciplinary colleagues are developing a trial for patients with good prognosis glioma comparing quality of life (QOL) and the long-term effects of radiotherapy between patients treated with proton beam therapy (PBT) and modern, state of the art image-guided intensity-modulated photon radiotherapy (IMRT). Patients with glioma differ in important ways from other oncology patients and this may have important implications for this and other studies. Patients frequently report symptoms including headaches, seizures, personality and memory changes and often have complex neurological deficits affect...
Conclusion: IMRT-based CCRT resulted in higher survival rates in patients with advanced clinical stages of TESCC (i.e., IIIA–IIIC), namely, clinical T3, clinical T4, or lymph node involvement.
This Viewpoint discusses details of the Radiation Oncology Model, a 90-day episode-based alternative payment model proposed by the Centers for Medicare&Medicaid Services (CMS) intended to reduce inappropriate overuse of proton beam therapy, intensity-modulated radiation therapy (IMRT), and other expensive radiation oncology services.
CONCLUSION: Individual methods showed dosimetric advantages on certain aspects, and the UTCI of the BAO treatment plans are marginally greater in the case of maxillary sinus and parotid gland. However, if treatment time was included into consideration, VMAT plans would be recommended for cancers of the nasopharynx, oral cavity, and larynx. PMID: 31593367 [PubMed - as supplied by publisher]
TORPEdO (TOxicity Reduction using Proton bEam therapy for Oropharyngeal cancer) is the UK's first proton clinical trial. It is a multicentre phase III trial of intensity-modulated proton beam therapy (IMPT) versus intensity-modulated radiotherapy (IMRT) for oropharyngeal squamous cell carcinoma (OPSCC).
CONCLUSIONS: Rapid analyses of automatically acquired Halcyon™ exit images could detect mid-treatment changes with high sensitivity, though appropriate thresholds will need to be set. This study presents the first steps toward developing effortless image evaluation for all aspects of every patient's treatment. PMID: 31587477 [PubMed - as supplied by publisher]